Heart Test Laboratories EBIT

Heart Test Laboratories (HSCS) currently reports a EBIT of $-1.9B as of January 2026. That compares with $-6.4B in the prior-year period — up 70.8% year over year. That is below the sector sector average of $-69M. Use the charts on this page to explore Heart Test Laboratories's EBIT history and peer comparisons.

Heart Test Laboratories's EBIT increased from $-6.4B to $-1.9B — a 70.8% year-over-year increase (period ending January 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Heart Test Laboratories's EBIT of $-1.9B is lower than the its sector sector average of $-69M. That is roughly 2624.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Heart Test Laboratories reported $-1.9B in EBIT as of January 2026. That compares with $-6.4B in the prior-year period — up 70.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-1.9B, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-69M. From there, open related valuation or income-statement pages for Heart Test Laboratories, and consider following HSCS for alerts when major investors trade the stock.